

Inflammation-targeting antibody found to improve preterm birth outcomes, prevent obesity-linked liver disease

June 22 2023



Elevated NAMPT hepatic expression in human subjects with NAFLD. (A) Normal liver tissue showing hepatocytes without steatosis (Human Normal). NAFLD liver tissue showing macrovesicular steatosis (long arrow), hepatocyte ballooning (short arrow), and focal lobular inflammation (arrowhead) (Human NAFLD) (bar—50 μ m). (B) Semi-quantification of steatosis in hepatocytes showing significantly higher percentages of hepatocytes involved with lipid accumulation in NAFLD livers compared with normal livers. (C) Immunohistochemistry (IHC) for NAMPT showed mild positivity (arrow) in normal liver tissue (Human Normal), but strong positivity (arrows) in liver with



NAFLD (Human NAFLD). (D) Image J software semi-quantitation of NAMPT immunostaining intensity represented as mean gray value confirmed significantly higher NAMPT staining in human NAFLD liver tissues compared to normal liver tissues (p

Citation: Inflammation-targeting antibody found to improve preterm birth outcomes, prevent obesity-linked liver disease (2023, June 22) retrieved 9 May 2024 from https://medicalxpress.com/news/2023-06-inflammation-targeting-antibody-preterm-birth-outcomes.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.